This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
pcv13
PCV13 (Prevnar 13)
13-valent pneumococcal conjugate vaccine (Prevnar 13); CPS from 13 S. pneumoniae serotypes conjugated to CRM197 toxoid. Enables T-cell-dependent infant immunization with memory. Reduced invasive pneumococcal disease >80% in children <5.
Entry Metadata
| Field | Value |
|---|---|
| ID | pcv13 |
| Name | PCV13 (Prevnar 13) |
| Status | active |
| Last reviewed | 2026-06-06 |
| Platform | 08-conjugate |
| Delivery system | protein-polysaccharide conjugate in aluminium phosphate adjuvant |
| Adjuvants | aluminium phosphate |
| Route | intramuscular |
| Dose schedule | 3+1 schedule (doses at 2, 4, 6 months + booster at 12–15 months); 2+1 acceptable in some programs |
| Manufacturer | Pfizer (formerly Wyeth) |
| Cold chain | 2–8°C; do not freeze (freezing denatures protein-polysaccharide conjugate) |
Cross-Atlas Connections
Sources
- Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. N Engl J Med. 2015;372(12):1114-1125. · PubMed 25785969
- Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada after the introduction of the 7-valent conjugate vaccine. CMAJ. 2009;180(2):E28-E37. · PubMed 19153394
- Pilishvili T, Lexau C, Farley MM, et al. Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine. J Infect Dis. 2010;201(1):32-41. · PubMed 19947881
- Pfizer. Prevnar 13 (pneumococcal 13-valent conjugate vaccine) package insert. Philadelphia, PA: Pfizer Inc; 2023.